Ken Griffin Rhythm Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 47,000 shares of RYTM stock, worth $2.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

47,000

Previous 43,500 8.05%

Holding current value

$2.8 Million

Previous $1.79 Million 37.85%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$40.81 - $55.0 $4.19 Million - $5.65 Million	102,778 New	102,778 $5.38 Million
Q1 2024 May 15, 2024	SELL	$39.12 - $52.44 $4.3 Million - $5.76 Million	-109,817 Reduced 96.4%	4,098 $177,000
Q4 2023 Feb 14, 2024	SELL	$21.39 - $49.64 $3.03 Million - $7.02 Million	-141,518 Reduced 55.4%	113,915 $5.24 Million
Q3 2023 Nov 14, 2023	BUY	$15.81 - $27.8 $1.04 Million - $1.83 Million	65,901 Added 34.77%	255,433 $5.85 Million
Q2 2023 Aug 14, 2023	SELL	$16.32 - $21.15 $2.86 Million - $3.71 Million	-175,508 Reduced 48.08%	189,532 $3.13 Million
Q1 2023 May 15, 2023	BUY	$16.88 - $34.24 $4.97 Million - $10.1 Million	294,342 Added 416.34%	365,040 $6.51 Million
Q4 2022 Feb 14, 2023	BUY	$22.21 - $30.25 $330,107 - $449,605	14,863 Added 26.62%	70,698 $2.06 Million
Q3 2022 Nov 14, 2022	SELL	$4.3 - $30.85 $482,558 - $3.46 Million	-112,223 Reduced 66.78%	55,835 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$3.12 - $12.25 $255,421 - $1 Million	-81,866 Reduced 32.76%	168,058 $698,000
Q1 2022 May 16, 2022	BUY	$6.13 - $12.24 $1.33 Million - $2.66 Million	217,350 Added 667.25%	249,924 $2.88 Million
Q2 2021 Aug 16, 2021	SELL	$18.52 - $22.55 $1.6 Million - $1.94 Million	-86,134 Reduced 72.56%	32,574 $637,000
Q1 2021 May 17, 2021	BUY	$20.25 - $39.49 $823,405 - $1.61 Million	40,662 Added 52.1%	118,708 $2.53 Million
Q4 2020 Feb 16, 2021	BUY	$21.17 - $32.61 $1.05 Million - $1.62 Million	49,648 Added 174.83%	78,046 $2.32 Million
Q3 2020 Nov 16, 2020	BUY	$18.13 - $30.61 $514,855 - $869,262	28,398 New	28,398 $615,000
Q2 2020 Aug 14, 2020	SELL	$14.41 - $25.35 $299,122 - $526,215	-20,758 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$13.16 - $22.9 $82,078 - $142,827	6,237 Added 42.95%	20,758 $316,000
Q4 2018 Feb 14, 2019	BUY	$24.11 - $31.34 $16,177 - $21,029	671 Added 4.84%	14,521 $390,000
Q3 2018 Nov 13, 2018	SELL	$26.99 - $35.85 $981,491 - $1.3 Million	-36,365 Reduced 72.42%	13,850 $0
Q2 2018 Aug 10, 2018	SELL	$17.02 - $35.2 $69,509 - $143,756	-4,084 Reduced 7.52%	50,215 $0
Q1 2018 May 11, 2018	SELL	$19.9 - $32.25 $2.94 Million - $4.76 Million	-147,529 Reduced 73.1%	54,299 $1.08 Million
Q4 2017 Feb 09, 2018	BUY	$22.0 - $30.51 $4.44 Million - $6.16 Million	201,828	201,828 $5.87 Million

Others Institutions Holding RYTM

# of Institutions

192

Shares Held

67.3M

Call Options Held

834K

Put Options Held

78.6K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.31B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account